Most Read Articles
07 Sep 2019
Eating mushrooms has no correlation with biomarkers and risks of cardiovascular disease (CVD) and type 2 diabetes (T2D) in adults, a US study has shown.
03 Sep 2019
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Rachel Soon, 4 days ago

Adding simvastatin as an adjuvant to standard triple therapy in Helicobacter pylori treatment may help compensate for increasing antimicrobial resistance, according to a new study.

Christina Lau, 03 Sep 2019
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.

Age, sex do not affect outcomes after PCI, CABG

23 Aug 2019

Age and sex do not appear to influence outcomes after percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) for left main coronary artery (LMCA) disease, reports a recent study.

The study included 4,001 LMCA patients who underwent either PCI (n=2,615; mean age, 63.7±10.8 years; 77.3 percent male) or CABG (n=1,386; mean age, 64.6±9.1 years; 77.8 percent male) for treatment. Participants were divided according to tertiles of age (<60, 60–69, 70 years) and according to sex. The primary outcome was a composite of death from any cause, stroke or myocardial infarction.

Over a median follow-up of 6.3 years, the primary composite endpoint occurred significantly more frequently in patients who received CABG vs PCI (14.5 percent vs 10.8 percent; p=0.001). This was also true in males (15.0 percent vs 11.0 percent; p=0.002) but not in females (12.8 percent vs 10.1 percent; p=0.17).

The difference in incidence of the primary outcome was only significant in participants aged <60 years (CABG vs PCI: 7.7 percent vs 4.0 percent; p=0.009).

However, multivariable Cox regression analysis found that there was no significant difference in the risk of the primary composite outcome between the PCI and CABG groups (adjusted hazard ratio [HR], 0.94, 95 percent CI, 0.75–1.16; p=0.55). This remained consistent across all age groups examined (p-interaction=0.57).

Stratifying according to sex likewise yielded meaningful changes. The risk of the primary outcome was comparable between PCI and CABG in both males (adjusted HR, 0.92, 0.72–1.17; p=0.47) and females (adjusted HR, 0.89, 0.52–1.50; p=0.65; p-interaction with sex=0.65).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
07 Sep 2019
Eating mushrooms has no correlation with biomarkers and risks of cardiovascular disease (CVD) and type 2 diabetes (T2D) in adults, a US study has shown.
03 Sep 2019
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Rachel Soon, 4 days ago

Adding simvastatin as an adjuvant to standard triple therapy in Helicobacter pylori treatment may help compensate for increasing antimicrobial resistance, according to a new study.

Christina Lau, 03 Sep 2019
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.